HHS In role
Alicia Jackson
Director, Advanced Research Projects Agency for Health (ARPA-H)
Materials scientist (Ph.D., MIT), former DARPA Biological Technologies Office program manager and deputy director, and founder-CEO of the women's-health company Evernow, serving as Director of ARPA-H since October 20, 2025. She runs the federal government's high-risk health research agency — its program managers, milestone-based awards, and a portfolio aimed at transforming clinical trials, aging, and research itself.
Role status — October 2026: Jackson is the Director of ARPA-H, sworn in on October 20, 2025. She is the agency’s second permanent director: inaugural director Renee Wegrzyn was dismissed in February 2025, and Jason Roos served as acting director until Jackson’s appointment, which HHS announced with Secretary Kennedy calling her “a visionary” for biotechnology breakthroughs. She remained in the role through October 2026, fronting the agency’s largest announcements.
Jackson’s background is the DARPA model she now runs for health. At DARPA she served as a program manager and then deputy director of the Biological Technologies Office, guiding investments across biodefense, novel medicine development, and biomanufacturing. She has also served as a Senate policy advisor and co-founded or advised several startups — OOVA, ImmuneBridge, and Drawbridge Health among them — and she joins ARPA-H directly from Evernow, the menopause-focused women’s-health company she founded and led as CEO. Her Ph.D. is in materials science from MIT.
ARPA-H, established inside HHS in 2022, funds platform technologies meant to transform areas of medicine that traditional research and commercial markets cannot readily reach; its roughly 30 program managers — her word for them is the agency’s “life and blood” — run milestone-based programs of two to six years. Her record in the job is a string of launches: EVIDENT (up to $100 million for quantitative mental-health measurement, November 2025); the PROSPR team awards (up to $144 million over five years for healthspan research, February 2026); IGoR, an AI-powered research ecosystem meant to speed discovery “at least ten times faster” (May 2026); REST, for closed-loop in-home sleep technology (June 2026); and the September 30, 2026 SURPASS suite — simulation-augmented adaptive clinical trials plus three companion projects — which she called “probably the largest suite of investments that we’ve made in a singular area.” In October 2026 she appeared alongside NIH Director Jay Bhattacharya for the women’s-health executive order, saying ARPA-H would put $100–200 million toward efforts that impact women.
Why tracked here: Jackson decides where the government’s riskiest health-research money goes — clinical trials, aging, AI research infrastructure — and her DARPA-style choices will shape which breakthrough bets the Kennedy HHS is remembered for placing.
Sources (Oct 2026): ARPA-H director bio and agency timeline; HHS leadership page; Fierce Biotech, Jan. 2026 and Oct. 7, 2026; ARPA-H program announcements, Nov. 2025–Sept. 2026; CBS News (via WGHN), Oct. 19, 2026.